Macquarie: market has oversold Resmed (RMD) as results came in lower that analyst expectations. We think underlying market demand remains strong and comp bidding-related headwinds will dissipate considerably in the coming months. Outperform.
I'm the Managing Director and Co-Founder of Livewire. I'm passionate about collecting and curating the markets most informed insights every day so that our members can discover new investment ideas. If you would like to get in touch - please use...
UBS have also upgraded to a BUY rating as the company managed to lift its gross margins underpinning estimates. In UBS's view, the case of ResMed has now become one of shorter term headwinds against longer term value.